x
Book Now
Send Now
Bulls Stadium, California
666-888-0000
info@example.com
Our Company
About Us
Partnership
Leadership
Facilities
R&D
Products & Pipeline
Biosimilars
505(b)(2)
Complex Programs
mRNA
Career
News
Contact
Contact Info
20 New England Ave.
Piscataway, NJ 08854
+1 000
info@kashivbio.com
News
Kashiv BioSciences
> News
Press Releases
Kashiv BioSciences Enters into Exclusive Licensing Agreement with
Alvotech for Development & Commercialization of a Proposed Biosimilar
to Xolair
®
(omalizumab)
Learn More
Kashiv BioSciences Enrolls First Patient in Phase III Clinical Study for ADL018, A Biosimilar Candidate to Xolair
®
(omalizumab)
Learn More
Kashiv Biosciences Announces Successful Phase 1 Study Results of ADL018, A Biosimilar Candidate to Xolair
®
(omalizumab)
Learn More
Kashiv BioSciences Achieves Second U.S. Biosimilar Approval with FYLNETRA
®
(pegfilgrastim-pbbk)
Learn More
Kashiv BioSciences Receives Approval for Its First Biosimilar RELEUKO
TM
(filgrastim-ayow)
Learn More
Filgrastim Biosimilar (Releuko®)- USFDA Approved
Kashiv Biosciences Receives Approval for Its First Biosimilar RELEUKO
TM
(filgrastim-ayow)
Know More
Pegfilgrastim Biosimilar (Fylnetra®)- USFDA Approved
Kashiv Biosciences Achieves Second U.S. Biosimilar Approval with FYLNETRA
®
(pegfilgrastim-pbbk)
Know More
